Document is current

Article History

Received: 9 May 2023

Accepted: 25 October 2023

First Online: 15 November 2023

Declarations

:

: The MEMENTO cohort protocol has been approved by the local ethics committee (“Comité de Protection des Personnes Sud-Ouest et Outre Mer III”; approval number 2010-A01394-35) and was registered in ClinicalTrials.gov (Identifier: NCT01926249). All participants provided written informed consent.

: Not applicable.

: Sandar Aye: has no competing interest to declare.Vincent Bouteloup: has no competing interest to declare.Ashley Tate: has no competing interest to declare.Anders Wimo: has received licence fees for the Resource Utilization in Dementia (RUD) instrument.Ron Handels: reports the following outside the study: funding (paid to department) from (private-)public frameworks JPND, IMI, H2020 (EU), ZonMw (NL), partly via affiliation at Karolinska Institutet; consulting fees (paid to department) from Lilly Nederland B.V. (advisory; 2022), institute for Medical Technology Assessment (advisory; 2021; content initiated by Biogen), Biogen Netherlands BV (advisory; 2021), Biogen MA Inc. (advisory; 2020), Eisai Inc. (advisory; 2019); member of ISPOR open-source modelling Special Interest Group (co-chair; 2022-now; unpaid), member of IPECAD modelling group (steering group; 2017-now; unpaid).Delphine Jean: has no competing interest to declare.Bengt Winblad: has received licence fees for the Resource Utilization in Dementia (RUD) instrument.Linus Jönsson: has received consulting fees from H. Lundbeck A/S and licence fees for the Resource Utilization in Dementia (RUD) instrument.